B1.351 (South Africa)

Background

South African variant is known as B.1.351 or 20H/501Y.V2.
This variant emerged with an unusually large number of mutations in South Africa.
As the variant spreads faster than other earlier variants of the virus, the variant may be driving the second wave of the pandemic in the country.
This variant is spreading globally (at least 32 different countries).
The variant was detected in 5 states, including California, in the U.S (a total of 13 cases).
Notable mutations: N501Y, K417N, and E484K in the receptor binding domain of spike protein, which can enhance its affinity to the human ACE2 receptor.
The E484K mutation might lead to escape from the immune response

Disease Severity

Currently, the ongoing studies suggest that the variant did not change the disease severity significantly. More studies are required to verify this.

Vaccine Efficacy

Currently, the ongoing studies suggest that the variant did not change the disease severity significantly. More studies are required to verify this.
So far, in vitro studies have shown that antibodies induced by all available vaccines ((Pfizer-BioNTech, Moderna, AstraZeneca-Oxford, Johnson and Johnson, Novavax) yield decreased neutralization activity on this variant in vitro.
In vivo studies conducted by Novavax, Johnson and Johnson and AstraZeneca have confirmed a decreased efficacy. Specifically, Novavax clinical trials showed that 89% efficacy in the UK and 60% efficacy in South Africa. Johnson and Johnson clinical trials showed that the level of protection against moderate to severe COVID-19 infection was 72% in the US, 66% in Latin America and 57% in South Africa, 28 days post-vaccination.
Currently, AstraZeneca vaccination was halted since clinical trials did not show protection against mild or moderate illness caused by the more contagious virus variant. However, scientists are reevaluating the data to reconsider the vaccination against more severe cases of COVID-19.
South Africa is considering using Johnson and Johnson vaccine (inexpensive; one dose vaccination; no requirement for freeze storage). Although the vaccine provided 57% efficacy against moderate to severe COVID-19, it provided a better protection (85% efficacy) against severe disease after 28 days post-vaccination

Therapeutic Efficacy

Most of the front-running antibody therapies for Covid-19 have shown to decrease in efficacy to the South African variant.
This has led to combine various monoclonal antibodies; as an example Casirivimab and imdevimab antibody cocktail (Regeneron) seems to be effective against the South African variant. Many more studies are needed to clarify these points.

Diagnostic Efficacy

The current molecular tests detect most of the variants and thus are able to diagnose COVID-19 infection by such variants. Yet, the fine identification of the type of variants is still based on sequence analysis although multiplex PCR test are being evaluated.
Indeed, the current variants of concern show distinctive mutations in the spike protein. Due to such mutations, most diagnostic tests for COVID-19 have been designed by targeting not only the spike protein but also other conserved proteins. For example, molecular tests designed to detect multiple SARS-CoV-2 genes (i.e., multiplex reverse transcription polymerase chain reaction targeting ORF1ab, N, and E genes) are less susceptible to the effects of genetic variation than tests designed to detect a single gene. The FDA is also monitoring the potential effects of genetic variation in molecular tests that have received Emergency Use Authorization and provides information about the tests.
Overall, the precise characterization of the variants still relies on genomic sequencing analysis. For instance, CDC is currently increasing sequence surveillance to more than 6000 samples per week to efficiently monitor the variants of concerns and other emerging variants. COVID-19 caused by variants in the U.S. can be found here

Publications

News